These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38490856)

  • 1. Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial.
    Möller F; Månsson M; Wallström J; Hellström M; Hugosson J; Arnsrud Godtman R
    Eur Urol; 2024 Aug; 86(2):95-100. PubMed ID: 38490856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
    Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
    Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
    Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
    JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
    Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
    JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial.
    Wallström J; Geterud K; Kohestani K; Maier SE; Pihl CG; Socratous A; Stranne J; Arnsrud-Godtman R; Månsson M; Hellström M; Hugosson J
    Eur Urol Oncol; 2022 Feb; 5(1):54-60. PubMed ID: 34580053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
    Boschheidgen M; Albers P; Schlemmer HP; Hellms S; Bonekamp D; Sauter A; Hadaschik B; Krilaviciute A; Radtke JP; Seibold P; Lakes J; Arsov C; Gschwend JE; Herkommer K; Makowski M; Kuczyk MA; Wacker F; Harke N; Debus J; Körber SA; Benner A; Kristiansen G; Giesel FL; Antoch G; Kaaks R; Becker N; Schimmöller L
    Eur Urol; 2024 Feb; 85(2):105-111. PubMed ID: 37863727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial.
    Josefsson A; Månsson M; Kohestani K; Spyratou V; Wallström J; Hellström M; Lilja H; Vickers A; Carlsson SV; Godtman R; Hugosson J
    Eur Urol; 2024 Sep; 86(3):223-229. PubMed ID: 38772787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
    Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
    Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the Göteborg-1 Prostate Cancer Screening Trial.
    Godtman RA; Kollberg KS; Pihl CG; Månsson M; Hugosson J
    Eur Urol; 2022 Sep; 82(3):311-317. PubMed ID: 35120773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
    Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS;
    JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
    Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
    JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results after Four Years of Screening for Prostate Cancer with PSA and MRI.
    Hugosson J; Godtman RA; Wallstrom J; Axcrona U; Bergh A; Egevad L; Geterud K; Khatami A; Socratous A; Spyratou V; Svensson L; Stranne J; Månsson M; Hellstrom M
    N Engl J Med; 2024 Sep; 391(12):1083-1095. PubMed ID: 39321360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING).
    Wetterauer C; Matthias M; Pueschel H; Deckart A; Bubendorf L; Mortezavi A; Arbelaez E; Jean Winkel D; Heye T; Boll DT; Merkle E; Hayoz S; Seifert HH; Rentsch CA
    Eur Urol Focus; 2024 Mar; 10(2):332-338. PubMed ID: 38402105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study.
    Eldred-Evans D; Tam H; Sokhi H; Padhani AR; Connor M; Price D; Gammon M; Klimowska-Nassar N; Burak P; Day E; Winkler M; Fiorentino F; Ahmed HU
    Eur Urol Oncol; 2023 Jun; 6(3):295-302. PubMed ID: 37080821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.
    Rannikko A; Leht M; Mirtti T; Kenttämies A; Tolonen T; Rinta-Kiikka I; Kilpeläinen TP; Natunen K; Lilja H; Lehtimäki T; Raitanen J; Kujala P; Ronkainen J; Matikainen M; Petas A; Taari K; Tammela T; Auvinen A
    BJU Int; 2022 Aug; 130(2):193-199. PubMed ID: 34958531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
    Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.